Ficolin B in Diabetic Kidney Disease in a Mouse Model of Type 1 Diabetes
Table 1
Table illustrating mean (95% confidence intervals).
Groups
Two-way ANOVA
Student's -test
Wild-type diabetic
Wild-type nondiabetic
Knockout diabetic
Knockout nondiabetic
Interaction (KO * dia)
diabetes (WT><KO)
control (WT><KO)
Body weight (g)
Start
20.6 (19.8; 21.4)
21 (20.2; 21.8)
20.2 (19.5; 20.8)
19.8 (19.1; 20.4)
0.38
0.43
0.05
End
21.1 (19.9; 22.4)
23.8 (23.0; 24.6)
19.1 (18.0; 20.3)
23.2 (22.3; 24.2)
0.22
0.05
0.34
Blood glucose (mmol/L)
Start
6.8 (6.5; 7.2)
6.4 (5.9; 6.9)
5.2 (4.6; 5.8)
5.7 (5.1; 6.4)
0.08
<0.001
0.12
End
23.8 (20.8; 26.8)
5.5 (4.9; 6.1)
26.3 (20.1; 32.5)
6.5 (6.0; 7.1)
0.60
0.41
0.04
AUC
2526 (2358; 2692)
765 (698; 833)
2581 (2367; 2795)
660 (628; 691)
0.25
0.69
0.13
Kidney weight (mg)
End
148.0 (136.8; 159.2)
118.9 (112.6; 125.2)
153.2 (137.0; 169.4)
118.3 (107.6; 129.0)
0.60
0.59
0.92
Albumin-to-creatinine ratio (mg/g)
End
76.3 (49.6; 103.1)
43.8 (25.1; 62.6)
96.4 (70.8; 122.1)
33.9 (23.3; 44.5)
0.21
0.34
0.44
Interaction (KO dia): two-way ANOVA—the interaction between the knockout factor and the diabetic factor. Diabetes WT><KO: Student’s -test of the diabetic wild-type mice compared to diabetic ficolin B knockout mice. Control WT><KO: Student’s -test of the control wild-type mice compared to the control ficolin B knockout mice.
AUC: blood glucose measured as area under the curve (daysmmol/L).
